Our study further strengthens the implication of ADME genes in the clinical outcome of various cancers [55] and highlights the importance of PXR as a potential biomarker of response to anticancer treatments in prostate cancers, in particular kinase inhibitors that are still the object of many clinical trials for castration-resistant tumors. Here, NR1I2 is linked to prostate carcinoma.